Safety, Tolerability and Efficacy of the Depigmented Modified Allergen Extract of Two Mites in Subjects With Allergic Rhinitis or Rhinoconjunctivitis, With Controlled Allergic Asthma

Exclusion Criteria

• •1. Any contraindication for treatment with allergen specific immunotherapy.
• •2. Subjects with a previous history of anaphylaxis.
• •3. Patients with hospital admission due to asthma exacerbations within 1 year prior to V1.
• •4. Has uncontrolled asthma, according to Global Initiative for Asthma Guidelines (GINA 2010).
• •5. Acute or chronic infectious conjunctivitis.
• •6. Has acute or chronic inflammatory or infectious airways disease.
• •7. Has chronic structural diseases of the affected organ (e.g. eye, nose, lung).
• •8. History or presence of confirmed or potential diseases of the immune system including autoimmune diseases and immune deficiencies of actual clinical relevance.
• •9. Has any disease that prohibits the use of adrenaline (e.g., hyperthyroidism).
• •10. Has a severe uncontrolled disease that could increase the risk to the subjects while participating in the study, including but not limited to, the following: cardiovascular insufficiency, any severe or unstable lung diseases, endocrine diseases, clinically significant renal or hepatic diseases or haematological disord